These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 22087078)

  • 1. Rapid diagnosis of tuberculosis with the Xpert MTB/RIF assay in high burden countries: a cost-effectiveness analysis.
    Vassall A; van Kampen S; Sohn H; Michael JS; John KR; den Boon S; Davis JL; Whitelaw A; Nicol MP; Gler MT; Khaliqov A; Zamudio C; Perkins MD; Boehme CC; Cobelens F
    PLoS Med; 2011 Nov; 8(11):e1001120. PubMed ID: 22087078
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population health impact and cost-effectiveness of tuberculosis diagnosis with Xpert MTB/RIF: a dynamic simulation and economic evaluation.
    Menzies NA; Cohen T; Lin HH; Murray M; Salomon JA
    PLoS Med; 2012; 9(11):e1001347. PubMed ID: 23185139
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modeling the patient and health system impacts of alternative xpert® MTB/RIF algorithms for the diagnosis of pulmonary tuberculosis in Addis Ababa, Ethiopia.
    Tesfaye A; Fiseha D; Assefa D; Klinkenberg E; Balanco S; Langley I
    BMC Infect Dis; 2017 May; 17(1):318. PubMed ID: 28464797
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of novel algorithms for rapid diagnosis of tuberculosis in HIV-infected individuals in Uganda.
    Shah M; Dowdy D; Joloba M; Ssengooba W; Manabe YC; Ellner J; Dorman SE
    AIDS; 2013 Nov; 27(18):2883-92. PubMed ID: 25119690
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Microscopic observation drug-susceptibility assay vs. Xpert
    Wikman-Jorgensen PE; Llenas-García J; Pérez-Porcuna TM; Hobbins M; Ehmer J; Mussa MA; Ascaso C
    Trop Med Int Health; 2017 Jun; 22(6):734-743. PubMed ID: 28380276
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Delayed diagnosis and treatment of tuberculosis in HIV+ patients in Mozambique: A cost-effectiveness analysis of screening protocols based on four symptom screening, smear microscopy, urine LAM test and Xpert MTB/RIF.
    Orlando S; Triulzi I; Ciccacci F; Palla I; Palombi L; Marazzi MC; Giuliano M; Floridia M; Mancinelli S; Mutemba E; Turchetti G
    PLoS One; 2018; 13(7):e0200523. PubMed ID: 30024890
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimal triage test characteristics to improve the cost-effectiveness of the Xpert MTB/RIF assay for TB diagnosis: a decision analysis.
    van't Hoog AH; Cobelens F; Vassall A; van Kampen S; Dorman SE; Alland D; Ellner J
    PLoS One; 2013; 8(12):e82786. PubMed ID: 24367555
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Point-of-care Xpert® MTB/RIF for smear-negative tuberculosis suspects at a primary care clinic in South Africa.
    Van Rie A; Page-Shipp L; Hanrahan CF; Schnippel K; Dansey H; Bassett J; Clouse K; Scott L; Stevens W; Sanne I
    Int J Tuberc Lung Dis; 2013 Mar; 17(3):368-72. PubMed ID: 23407225
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Costs and cost-effectiveness of Gene Xpert compared to smear microscopy for the diagnosis of pulmonary tuberculosis using real-world data from Arsi zone, Ethiopia.
    Kaso AW; Hailu A
    PLoS One; 2021; 16(10):e0259056. PubMed ID: 34695153
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness analysis of microscopic observation drug susceptibility test versus Xpert MTB/Rif test for diagnosis of pulmonary tuberculosis in HIV patients in Uganda.
    Walusimbi S; Kwesiga B; Rodrigues R; Haile M; de Costa A; Bogg L; Katamba A
    BMC Health Serv Res; 2016 Oct; 16(1):563. PubMed ID: 27724908
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Point of care Xpert MTB/RIF versus smear microscopy for tuberculosis diagnosis in southern African primary care clinics: a multicentre economic evaluation.
    Pooran A; Theron G; Zijenah L; Chanda D; Clowes P; Mwenge L; Mutenherwa F; Lecesse P; Metcalfe J; Sohn H; Hoelscher M; Pym A; Peter J; Dowdy D; Dheda K
    Lancet Glob Health; 2019 Jun; 7(6):e798-e807. PubMed ID: 31097281
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-benefit analysis of Xpert MTB/RIF for tuberculosis suspects in German hospitals.
    Diel R; Nienhaus A; Hillemann D; Richter E
    Eur Respir J; 2016 Feb; 47(2):575-87. PubMed ID: 26647440
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rapid, point-of-care diagnosis of tuberculosis with novel Truenat assay: Cost-effectiveness analysis for India's public sector.
    Lee DJ; Kumarasamy N; Resch SC; Sivaramakrishnan GN; Mayer KH; Tripathy S; Paltiel AD; Freedberg KA; Reddy KP
    PLoS One; 2019; 14(7):e0218890. PubMed ID: 31265470
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparing laboratory costs of smear/culture and Xpert
    Naidoo P; Dunbar R; du Toit E; van Niekerk M; Squire SB; Beyers N; Madan J
    Int J Tuberc Lung Dis; 2016 Oct; 20(10):1377-1385. PubMed ID: 27725051
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of Xpert MTB/RIF with other nucleic acid technologies for diagnosing pulmonary tuberculosis in a high HIV prevalence setting: a prospective study.
    Scott LE; McCarthy K; Gous N; Nduna M; Van Rie A; Sanne I; Venter WF; Duse A; Stevens W
    PLoS Med; 2011 Jul; 8(7):e1001061. PubMed ID: 21814495
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Burden of tuberculosis in intensive care units in Cape Town, South Africa, and assessment of the accuracy and effect on patient outcomes of the Xpert MTB/RIF test on tracheal aspirate samples for diagnosis of pulmonary tuberculosis: a prospective burden of disease study with a nested randomised controlled trial.
    Calligaro GL; Theron G; Khalfey H; Peter J; Meldau R; Matinyenya B; Davids M; Smith L; Pooran A; Lesosky M; Esmail A; Miller MG; Piercy J; Michell L; Dawson R; Raine RI; Joubert I; Dheda K
    Lancet Respir Med; 2015 Aug; 3(8):621-30. PubMed ID: 26208996
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the Xpert MTB/RIF assay for the diagnosis of pulmonary tuberculosis in a high HIV prevalence setting.
    Theron G; Peter J; van Zyl-Smit R; Mishra H; Streicher E; Murray S; Dawson R; Whitelaw A; Hoelscher M; Sharma S; Pai M; Warren R; Dheda K
    Am J Respir Crit Care Med; 2011 Jul; 184(1):132-40. PubMed ID: 21493734
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The cost-effectiveness of routine tuberculosis screening with Xpert MTB/RIF prior to initiation of antiretroviral therapy: a model-based analysis.
    Andrews JR; Lawn SD; Rusu C; Wood R; Noubary F; Bender MA; Horsburgh CR; Losina E; Freedberg KA; Walensky RP
    AIDS; 2012 May; 26(8):987-95. PubMed ID: 22333751
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Accuracy of different Xpert MTB/Rif implementation strategies in programmatic settings at the regional referral hospitals in Uganda: Evidence for country wide roll out.
    Muttamba W; Ssengooba W; Sekibira R; Kirenga B; Katamba A; Joloba M
    PLoS One; 2018; 13(3):e0194741. PubMed ID: 29566056
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimizing tuberculosis case detection through a novel diagnostic device placement model: the case of Uganda.
    Pho MT; Deo S; Palamountain KM; Joloba ML; Bajunirwe F; Katamba A
    PLoS One; 2015; 10(4):e0122574. PubMed ID: 25830297
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.